Drugs / AD 337
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00377039 | Aug 2006 → Aug 2007 | fibromyalgia | Sosei | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2007-09-18 | Nxera Pharma UK Limited | Results Other nxera.life ↗ |
| 2007-09-08 | Nxera Pharma UK Limited | Results Sosei Announces Completion of Phase II Trialof AD 337 in Fibromyalgia Syndrome nxera.life ↗
Results show that the study did not achieve a statistically significant outcome in its primary endpoint at 4 weeks. |
| 2005-11-01 | Nxera Pharma UK Limited | Results Other nxera.life ↗ |
| 2005-11-01 | Nxera Pharma UK Limited | Results Arakis Completes Phase I Trials of AD 337 in Fibromyalgia Syndrome nxera.life ↗
AD 337 was observed to be well tolerated. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-09-18 | Nxera Pharma UK Limited | Other nxera.life ↗ |
| 2007-09-08 | Nxera Pharma UK Limited | Sosei Announces Completion of Phase II Trialof AD 337 in Fibromyalgia Syndrome nxera.life ↗ |
| 2006-10-17 | Nxera Pharma UK Limited | Sosei Announces Start of Phase II Trial of AD 337 in Fibromyalgia Syndrome nxera.life ↗ |
| 2005-11-01 | Nxera Pharma UK Limited | Other nxera.life ↗ |
| 2005-11-01 | Nxera Pharma UK Limited | Arakis Completes Phase I Trials of AD 337 in Fibromyalgia Syndrome nxera.life ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD 337 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00377039 ↗ |